B. Riley Wealth Advisors Inc. Reduces Stake in Sanofi (NASDAQ:SNY)

B. Riley Wealth Advisors Inc. lessened its position in shares of Sanofi (NASDAQ:SNY) by 18.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 13,671 shares of the company’s stock after selling 3,051 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Sanofi were worth $776,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC grew its stake in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC boosted its holdings in shares of Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the period. Jennison Associates LLC raised its holdings in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after buying an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after purchasing an additional 1,424,289 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

SNY opened at $48.94 on Wednesday. The business has a 50 day moving average price of $50.72 and a two-hundred day moving average price of $52.09. The company has a market capitalization of $124.20 billion, a price-to-earnings ratio of 24.97, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the prior year, the business earned $2.55 EPS. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. Research analysts predict that Sanofi will post 4.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.